Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2018 1
2019 2
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean stefania cosenza (5 results)?
Monoclonal antibodies in gastrointestinal cancers.
Bronte G, Cicero G, Cusenza S, Galvano A, Musso E, Rizzo S, Sortino G, Roselli M, Bazan V, Fiorentino E, Russo A. Bronte G, et al. Among authors: cusenza s. Expert Opin Biol Ther. 2013 Jun;13(6):889-900. doi: 10.1517/14712598.2013.774367. Epub 2013 Feb 27. Expert Opin Biol Ther. 2013. PMID: 23441760 Free article. Review.
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials.
Galvano A, Scaturro D, Badalamenti G, Incorvaia L, Rizzo S, Castellana L, Cusenza S, Cutaia S, Santini D, Guadagni F, Roselli M, Gori S, Latteri MA, Bazan V, Giulia LM, Russo A. Galvano A, et al. Among authors: cusenza s. J Bone Oncol. 2019 Jul 16;18:100252. doi: 10.1016/j.jbo.2019.100252. eCollection 2019 Oct. J Bone Oncol. 2019. PMID: 31440444 Free PMC article. Review.
Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses.
Gristina V, Galvano A, Castellana L, Insalaco L, Cusenza S, Graceffa G, Iacono F, Barraco N, Castiglia M, Perez A, Rizzo S, Russo A, Bazan V. Gristina V, et al. Among authors: cusenza s. Ther Adv Med Oncol. 2021 Jul 21;13:17588359211018018. doi: 10.1177/17588359211018018. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34646363 Free PMC article.
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients.
Incorvaia L, Fanale D, Bono M, Calò V, Fiorino A, Brando C, Corsini LR, Cutaia S, Cancelliere D, Pivetti A, Filorizzo C, La Mantia M, Barraco N, Cusenza S, Badalamenti G, Russo A, Bazan V. Incorvaia L, et al. Among authors: cusenza s. Ther Adv Med Oncol. 2020 Dec 16;12:1758835920975326. doi: 10.1177/1758835920975326. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33403015 Free PMC article.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. De Placido S, et al. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Lancet Oncol. 2018. PMID: 29482983 Clinical Trial.